Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Biqin Li

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Bioorganic & Medicinal Chemistry Letters|April 28, 2004
A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejectionDavid W Borhani, David J Calderwood, Michael M Friedman, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2008
Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonistsPatrick Betschmann, Brian Bettencourt, Diana Donnelly-Roberts, et al.
Journal of Medicinal Chemistry|February 8, 2022
Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody-Drug Conjugate PayloadsAdrian D Hobson, Michael J McPherson, Wendy Waegell, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2009
2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding modeMaria A Argiriadi, Anna M Ericsson, Christopher M Harris, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2009
2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimizationChristopher M Harris, Anna M Ericsson, Maria A Argiriadi, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Bioorganic & Medicinal Chemistry Letters|April 28, 2004
A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejectionDavid W Borhani, David J Calderwood, Michael M Friedman, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2008
Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonistsPatrick Betschmann, Brian Bettencourt, Diana Donnelly-Roberts, et al.
Journal of Medicinal Chemistry|February 8, 2022
Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody-Drug Conjugate PayloadsAdrian D Hobson, Michael J McPherson, Wendy Waegell, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2009
2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding modeMaria A Argiriadi, Anna M Ericsson, Christopher M Harris, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2009
2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimizationChristopher M Harris, Anna M Ericsson, Maria A Argiriadi, et al.
Pageof 2